Participants in this study have a hematologic malignancy which is a disorder in the bone marrow that affects the body's ability to create blood. Participants might benefit from receiving an allogeneic stem cell transplant (meaning the cells come from a donor). The participants donor is a family member. Stem cells are cells in the bone marrow and blood that can form a whole new blood system.

Patients are given high doses of chemotherapy before receiving a stem cell transplant to keep their immune system from rejecting the donor stem cells and to kill any diseased cells that remain in the body. To try and improve on the results of transplants that use high dose chemotherapy alone, we are adding an agent called anti-CD45 to the treatment prior to the stem cell transplant. Anti-CD45 is an antibody that specifically finds and destroys leukemia cells.

Patients will receive the anti-CD45 with high dose chemotherapy (including Ara-C and Cyclophosphamide) and radiotherapy. Patients will also receive Mesna which is a drug that helps prevent bladder damage which can be caused by the cyclophosphamide. High dose radiotherapy is also known as Total Body Irradiation or TBI.

Patients will receive the anti-CD45, high dose chemotherapy, and high dose radiotherapy before the stem cell transplant. We expect participation in this study will last 2 years.

A summary of the treatment follows:

• Day - 7: Ara-C, Cyclophosphamide, Mesna
• Day - 6: Ara-C, Cyclophosphamide, Mesna
• Day - 5: Ara-C, Anti-CD45
• Day - 4: Anti-CD45, TBI
• Day - 3: Anti-CD45, TBI
• Day - 2: Anti-CD45, TBI
• Day - 1: TBI
• Day 0: Stem Cell Infusion (transplant)

Ages Eligible for Study:  up to  45 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion criteria:

• Patients with advanced leukemia or other hematologic malignancy including AML, ALL, CML, and MDS. Advanced features include: a) Induction failure, prolonged induction beyond 6 weeks b) Incomplete response to salvage therapy c) CML in blast crisis or acute leukemia in chemotherapy resistant relapse d) secondary leukemia or secondary myelodysplastic disease
• Patients with CD45 present on leukemic blasts at a level of >/= 95% as documented by flow cytometry
• Patients must have a suitable HLA identical sibling donor or 5/6 matched related donor, or fully matched or 5/6 matched unrelated donor

Exclusion criteria:

• Patients with a life expectancy (</= 6 weeks) limited by diseases other than leukemia
• Patients with T-cell lymphoblastic lymphoma
• Patients with symptomatic cardiac disease or evidence of significant cardiac disease by echocardiogram
• Patients with liver disease that on evaluation by the Principal Investigator precludes ablative radio/chemotherapy or successful transplantation
• Patients with severe renal disease (Creatinine > 2x normal for age)
• Patients with known allergy to rat serum products
• Patients with a Lansky score <60% or Karnofsky score <60%
• Patients with severe infection that on evaluation by the PI precludes ablative radio/chemotherapy or successful transplantation
• Patients with severe personality disorder or mental illness
• Patients with documented HIV positivity
• Pregnant or lactating females